Dyne Therapeutics (NASDAQ:DYN) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Dyne Therapeutics (NASDAQ:DYN) issued its quarterly earnings data on Tuesday. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25), Zacks reports.

Dyne Therapeutics Stock Down 11.2 %

Shares of DYN stock opened at $30.31 on Friday. Dyne Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $47.45. The stock’s fifty day moving average price is $32.58 and its two-hundred day moving average price is $35.08.

Insider Activity

In other news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This represents a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Morgan Stanley upped their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.